Dr. Sandhya Srinivas, MD

Medical Oncology Stanford, CA Female
NPI: 1205913589
Total Payments
$272,187
2024 Payments
$37,293
Companies
30
Transactions
284
Medicare Patients
2,105
Medicare Billing
$377,128

Payment Breakdown by Category

Consulting$201,547 (74.0%)
Travel$37,326 (13.7%)
Other$14,818 (5.4%)
Food & Beverage$9,640 (3.5%)
Research$8,837 (3.2%)
Education$18.93 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $201,547 91 74.0%
Travel and Lodging $37,326 61 13.7%
Honoraria $10,965 5 4.0%
Food and Beverage $9,640 115 3.5%
Unspecified $8,837 7 3.2%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,780 2 1.4%
Entertainment $72.73 1 0.0%
Education $18.93 2 0.0%

Payments by Type

General
$263,350
277 transactions
Research
$8,837
7 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $37,113 26 $0 (2024)
Eisai Inc. $28,108 31 $0 (2023)
Bayer HealthCare Pharmaceuticals Inc. $23,377 23 $0 (2021)
Merck Sharp & Dohme LLC $23,330 28 $0 (2022)
GE HEALTHCARE $18,965 7 $0 (2024)
Novartis Pharmaceuticals Corporation $17,431 9 $0 (2024)
Eli Lilly and Company $15,300 3 $0 (2024)
Janssen Biotech, Inc. $12,263 16 $0 (2019)
Exelixis Inc. $11,413 25 $0 (2023)
E.R. Squibb & Sons, L.L.C. $11,315 14 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $37,293 26 GE HEALTHCARE ($18,965)
2023 $20,843 19 NOVARTIS PHARMACEUTICALS CORPORATION ($5,392)
2022 $37,085 28 Eli Lilly and Company ($7,200)
2021 $36,785 20 PFIZER INC. ($8,673)
2020 $27,174 26 Bayer HealthCare Pharmaceuticals Inc. ($6,337)
2019 $53,854 67 EISAI INC. ($12,683)
2018 $26,175 46 Janssen Biotech, Inc. ($5,457)
2017 $32,978 52 Exelixis Inc. ($7,556)

All Payment Transactions

284 individual payment records from CMS Open Payments — Page 1 of 12

Date Company Product Nature Form Amount Type
12/05/2024 Aveo Pharmaceuticals, Inc. FOTIVDA (Drug) Food and Beverage In-kind items and services $34.47 General
Category: Oncology
11/21/2024 Telix Pharmaceuticals ILLUCCIX (Drug), ILLUCCIX Consulting Fee Cash or cash equivalent $2,600.00 General
Category: PROSTATE CANCER THERAPY
11/21/2024 Telix Pharmaceuticals ILLUCCIX (Drug), ILLUCCIX Consulting Fee Cash or cash equivalent $1,300.00 General
Category: PROSTATE CANCER THERAPY
11/08/2024 PFIZER INC. — Consulting Fee Cash or cash equivalent $1,908.00 General
11/06/2024 GE HEALTHCARE — Consulting Fee Cash or cash equivalent $500.00 General
11/06/2024 GE HEALTHCARE — Consulting Fee Cash or cash equivalent $500.00 General
10/14/2024 Eli Lilly and Company — Consulting Fee Cash or cash equivalent $4,500.00 General
09/21/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Food and Beverage In-kind items and services $105.09 General
Category: PROSTATE CANCER DIAGNOSIS
09/21/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Food and Beverage In-kind items and services $102.41 General
Category: PROSTATE CANCER DIAGNOSIS
09/21/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Food and Beverage In-kind items and services $72.58 General
Category: PROSTATE CANCER DIAGNOSIS
09/20/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Travel and Lodging Cash or cash equivalent $398.51 General
Category: PROSTATE CANCER DIAGNOSIS
09/20/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Food and Beverage In-kind items and services $169.42 General
Category: PROSTATE CANCER DIAGNOSIS
09/20/2024 Telix Pharmaceuticals ILLUCCIX (Drug) Travel and Lodging Cash or cash equivalent $165.91 General
Category: PROSTATE CANCER DIAGNOSIS
09/13/2024 PFIZER INC. PADCEV (Biological) — In-kind items and services $940.00 Research
Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology
09/11/2024 GE HEALTHCARE — Food and Beverage In-kind items and services $82.00 General
08/29/2024 Telix Pharmaceuticals ILLUCCIX (Drug), ILLUCCIX Travel and Lodging Cash or cash equivalent $530.95 General
Category: PROSTATE CANCER THERAPY
06/18/2024 GE HEALTHCARE — Travel and Lodging In-kind items and services $17,000.00 General
06/01/2024 Novartis Pharmaceuticals Corporation — Consulting Fee Cash or cash equivalent $2,000.00 General
06/01/2024 GE HEALTHCARE — Travel and Lodging In-kind items and services $631.00 General
06/01/2024 Novartis Pharmaceuticals Corporation — Travel and Lodging In-kind items and services $581.45 General
06/01/2024 Novartis Pharmaceuticals Corporation — Consulting Fee Cash or cash equivalent $322.85 General
06/01/2024 GE HEALTHCARE — Travel and Lodging In-kind items and services $165.00 General
06/01/2024 Novartis Pharmaceuticals Corporation — Food and Beverage In-kind items and services $135.00 General
06/01/2024 GE HEALTHCARE — Travel and Lodging In-kind items and services $87.00 General
03/12/2024 Regeneron Pharmaceuticals, Inc. LIBTAYO (Biological) — In-kind items and services $234.49 Research
Study: PHASE 1/2 STUDY OF REGN4336 (A PSMAXCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER • Category: ONCOLOGY
123…12»

Research Studies & Clinical Trials

Study Name Company Amount Records
PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH Novartis Pharmaceuticals Corporation $5,820 1
PADCEV CLINICAL PUBLICATION PROGRAM PFIZER INC. $940.00 1
A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4 Astellas Pharma Global Development $852.50 1
Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Astellas Pharma Global Development $818.73 1
PHASE 1/2 STUDY OF REGN4336 (A PSMAXCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Regeneron Pharmaceuticals, Inc. $234.49 1
ASP1941 Phase II Clinical Study A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients with Type 2 Diabetes Mellitus Astellas Pharma Global Development $170.83 2

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 440 1,039 $591,403 $96,289
2022 8 637 1,187 $648,031 $108,894
2021 9 642 1,194 $619,895 $102,893
2020 4 386 947 $325,481 $69,052
Total Patients
2,105
Total Services
4,367
Medicare Billing
$377,128
Procedure Codes
27

All Medicare Procedures & Services

27 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 259 717 $446,262 $60,337 13.5%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 44 183 $68,397 $20,075 29.4%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 80 80 $46,810 $9,213 19.7%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 26 26 $19,682 $4,158 21.1%
99238 Hospital discharge day management, 30 minutes or less Facility 2023 31 33 $10,252 $2,505 24.4%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 186 408 $252,800 $35,364 14.0%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 61 293 $107,824 $27,388 25.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 88 117 $92,518 $15,242 16.5%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 141 206 $95,174 $10,767 11.3%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2022 76 76 $55,832 $9,134 16.4%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 41 42 $29,616 $7,655 25.8%
99238 Hospital discharge day management, 30 minutes or less Facility 2022 33 34 $9,764 $2,265 23.2%
99239 Hospital discharge day management, more than 30 minutes Facility 2022 11 11 $4,503 $1,080 24.0%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 182 387 $229,344 $32,891 14.3%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 196 402 $180,096 $23,549 13.1%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 59 184 $67,712 $17,448 25.8%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 59 75 $59,700 $10,294 17.2%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 46 46 $30,268 $8,360 27.6%
99204 New patient outpatient visit, total time 45-59 minutes Facility 2021 51 51 $33,882 $6,383 18.8%
99239 Hospital discharge day management, more than 30 minutes Facility 2021 15 15 $6,045 $1,501 24.8%
99238 Hospital discharge day management, 30 minutes or less Facility 2021 18 18 $4,788 $1,257 26.2%
99203 New patient outpatient visit, total time 30-44 minutes Facility 2021 16 16 $8,060 $1,211 15.0%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 238 753 $231,545 $50,896 22.0%
99204 New patient office or other outpatient visit, typically 45 minutes Facility 2020 77 77 $35,644 $8,932 25.1%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 12 54 $19,872 $5,282 26.6%
12»

About Dr. Sandhya Srinivas, MD

Dr. Sandhya Srinivas, MD is a Medical Oncology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205913589.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandhya Srinivas, MD has received a total of $272,187 in payments from pharmaceutical and medical device companies, with $37,293 received in 2024. These payments were reported across 284 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($201,547).

As a Medicare-enrolled provider, Srinivas has provided services to 2,105 Medicare beneficiaries, totaling 4,367 services with total Medicare billing of $377,128. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Location Stanford, CA
  • Active Since 11/01/2006
  • Last Updated 04/12/2024
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1205913589

Products in Payments

  • Lenvima (Drug) $28,108
  • TECENTRIQ (Biological) $15,523
  • BAVENCIO (Drug) $13,475
  • Cabometyx (Drug) $9,783
  • PADCEV (Biological) $9,140
  • Non-Covered (Drug) $8,428
  • Erleada (Drug) $7,952
  • Nubeqa (Drug) $6,367
  • ILLUCCIX (Drug) $5,564
  • XTANDI (Drug) $5,456
  • PLUVICTO (Drug) $5,392
  • Xofigo (Drug) $5,389
  • FOTIVDA (Drug) $4,650
  • OPDIVO (Biological) $4,388
  • Balversa (Drug) $4,229
  • Lysodren (Drug) $3,500
  • ZYTIGA (Drug) $3,491
  • Non-Covered $3,193
  • Rubraca (Drug) $2,849
  • IMFINZI (Drug) $2,362

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Stanford

Ranjana Advani, Md, MD

Medical Oncology — Payments: $184,712

Medical Oncology $184,712

Kristen Ganjoo, Md, MD

Medical Oncology — Payments: $69,790

Medical Oncology $69,790

Heather Wakelee, Md, MD

Medical Oncology — Payments: $52,107

Medical Oncology $52,107

Arash Alizadeh, Md, Phd, MD, PHD

Medical Oncology — Payments: $46,821

Medical Oncology $46,821

Gregory Heestand, M.d, M.D

Medical Oncology — Payments: $34,424

Medical Oncology $34,424

Caroline Berube, Md, MD

Medical Oncology — Payments: $30,092

Medical Oncology $30,092